Happy 30th birthday, Pokémon! Since 1996, the Japanese media sensation has inspired generations of researchers in fields as diverse as evolution, biodiversity and research integrity. https://t.co/xDkf4D7VyT
@tranvinq@ScienceMagazine This is very cool! Congrats! I would be curious to see how many synergistic mutations would be needed to fix single point pathogenic mutations (without reverting the disease causing mutation). Perhaps, a bit of a niche wish, but I would find it interesting.
This went live today, on Thanksgiving, which feels quietly special.
This article is about one of my favorite topics: how human genetics is being used to shape drug development. It’s a synthesis of ideas and lessons that have emerged over many years, brought together into a single narrative.
I’m grateful for the opportunity to give structure to these thoughts — and excited about where human genetics–driven drug development is headed next. The future here feels genuinely promising.
Many thanks to the editors at @WorksInProgMag — @bswud and @salonium — for the opportunity and for helping edit this article into its best possible version.
Hope you enjoy this light read on Thanksgiving Day :)
🧬 Nature’s laboratory
https://t.co/X9Z2joGLgv
Putin and his murderous thugs are watching this and laughing their heads off. Trump and Vance are singing his songs at the top of their voices. “This is going to be great television” says Trump. All he cares about. Was talking to Michael Woolf earlier today. “You have to remember he is a reality TV star,” he said. “All he cares about is attention. And together get ratings you need conflict, conflict, conflict.” As for Vance … vile. Zelensky is a great man being treated to Mafia style bullying, intimidation and extortion. Europe has to stand up as one when Zelensky arrives in London on Sunday.
第二著者ではありますが、論文がNCBにPublishされました!
Happy to share our latest work from @francisabarr lab is now published in @NatureCellBio#cellcycle@BiochemOxford
👉MDM2 functions as a timer reporting the length of mitosis | Nature Cell Biology https://t.co/xqGQ9C1bsl
Fascinating read on Ionis' past, present and future. The upcoming FDA decision tomorrow on olezarsen (APOC3 ASO) for the treatment of familial chylomicronemia syndrome (FCS) is critical and will impact the company's financial path forward over the next years.
https://t.co/xkOpjn6Fsw
@christophclarey agree. it would also be fun to have more tactics factored in, allowing perhaps the underdog team of each Tie to decide in which order the matches are played (with the rule that n.1s have to play anyway either the 1st or 2nd match). Would be more responsibilities for the captains
RNA Editing Therapy Developer Closes $60M Series A Financing
AIRNA, a developer of RNA editing therapies whose lead program targets AATD, has closed an oversubscribed $60 million Series A financing. Learn more: https://t.co/PNRhICpYKY
When I was little, I watched this fantastic tournament on TV. Playing in the final here is a lifetime memory. I didn’t win, but it’s still a good day. Thanks to everyone cheering for me—family, team, and sponsors. Thank you, @Wimbledon. Grazie mille!
RNA-editing drugs advance into clinical trials https://t.co/0qiWSO3e1V
ADAR-based editors that can change the mRNA code offer new opportunities in both rare genetic diseases and common complex ones. Find out more in this news article published today